| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NOTCH2 |
| Uniprot No | Q04721 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-136aa |
| 氨基酸序列 | QCRDGYEPCVNEGMCVTYHNGTGYCKCPEGFLGEYCQHRDPCEKNRCQNG GTCVAQAMLGKATCRCASGFTGEDCQYSTSHPCFVSRPCLNGGTCHMLSR DTYECTCQVG |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NOTCH2重组蛋白的3篇代表性文献(虚构示例，仅供格式参考)：
1. **标题**：Structural Basis of Notch2 Activation by Delta-like Ligand 1
**作者**：Smith A, et al.
**摘要**：通过冷冻电镜解析NOTCH2与Delta-like ligand 1(DLL1)复合物的三维结构，揭示了NOTCH2胞外域构象变化如何触发跨膜信号传导的分子机制。
2. **标题**：Notch2 Signaling Promotes Cell Proliferation in Triple-Negative Breast Cancer
**作者**：Chen L, Wang Y.
**摘要**：研究发现重组NOTCH2蛋白通过激活Hes1通路增强三阴性乳腺癌细胞增殖，靶向NOTCH2可抑制小鼠模型肿瘤生长。
3. **标题**：Engineering Soluble NOTCH2 Extracellular Domain for Ligand Interaction Studies
**作者**：Johnson R, et al.
**摘要**：开发了一种可溶性重组NOTCH2胞外域蛋白，结合生物膜层干涉技术定量分析其与Jagged1的结合动力学，为药物筛选提供工具。
注：以上文献信息为模拟生成，实际引用请查询PubMed或专业数据库(如PMID 12345678)。
**Background of NOTCH2 Recombinant Protein**
The NOTCH2 protein is a critical component of the evolutionarily conserved NOTCH signaling pathway, which regulates cell-cell communication, differentiation, proliferation, and apoptosis. As a transmembrane receptor, NOTCH2 consists of an extracellular domain (ECD) with multiple epidermal growth factor (EGF)-like repeats, a transmembrane region, and an intracellular domain (NICD) responsible for transcriptional regulation. It interacts with ligands such as Jagged and Delta-like proteins on adjacent cells, triggering proteolytic cleavage events that release NICD. This fragment translocates to the nucleus, activating target genes like *HES* and *HEY* families, which influence cell fate decisions.
NOTCH2 plays distinct roles in development and tissue homeostasis, particularly in organogenesis (e.g., liver, kidney, skeleton) and immune cell regulation. Dysregulation of NOTCH2 is linked to diseases, including Alagille syndrome (developmental disorders) and Hajdu-Cheney syndrome (osteoporosis), caused by gain- or loss-of-function mutations. In cancer, NOTCH2 can act as an oncogene or tumor suppressor, depending on context, with aberrant signaling observed in breast, lung, and hematological malignancies.
Recombinant NOTCH2 proteins are engineered *in vitro* to study these mechanisms. They typically include functional domains like the ligand-binding EGF repeats or the transcriptionally active NICD. Produced in mammalian or insect cell systems, these proteins retain post-translational modifications (e.g., glycosylation) critical for activity. Researchers use them to investigate ligand-receptor interactions, pathway modulation, and therapeutic targeting. For example, NOTCH2-targeting antibodies (e.g., tarextumab) or inhibitors are explored in oncology, though clinical outcomes remain complex due to the pathway’s dual roles.
Challenges in NOTCH2 research include its crosstalk with other NOTCH receptors (NOTCH1. 3. 4) and context-dependent signaling effects. Recombinant tools help dissect these nuances, advancing drug discovery and mechanistic understanding of developmental and pathological processes.
×
